Ligand Pharmaceuticals (LGND) Other Non Operating Income (2010 - 2026)

Ligand Pharmaceuticals has disclosed Other Non Operating Income across 17 years of filings, most recently posting -$1.2 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$1.2 million, up 53.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (up 105.55% YoY), and the FY2025 annual result was -$89000.0, up 99.41% from the prior year.
• Other Non Operating Income came in at -$1.2 million for Q1 2026 at Ligand Pharmaceuticals, down from $1.5 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $4.6 million in Q4 2023 to a low of -$33.5 million in Q2 2024.
• The 5-year median for Other Non Operating Income is -$58000.0 (2022), against an average of -$2.5 million.
• Across the five-year window, Other Non Operating Income soared 676.29% in 2023 and sank 3739.98% in 2024, its largest moves.
• Ligand Pharmaceuticals' Other Non Operating Income stood at -$793000.0 in 2022, then jumped by 676.29% to $4.6 million in 2023, then tumbled by 131.73% to -$1.4 million in 2024, then jumped by 202.28% to $1.5 million in 2025, then tumbled by 179.23% to -$1.2 million in 2026.
• The last three Other Non Operating Income figures came in at -$1.2 million (Q1 2026), $1.5 million (Q4 2025), and $833000.0 (Q3 2025), per Business Quant data.